Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies

Blueprint Medicines Corporation BPMC and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies

  • The collaboration will bring Proteovant's Artificial Intelligence (AI)-enhanced targeted protein degradation (TPD) platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. 
  • The companies will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. 
  • Proteovant's exclusive partner for TPD, VantAI, will deploy its leading AI technologies for degrader generation and optimization.
  • Upon designation of a clinical development candidate, Blueprint Medicines has the exclusive option to develop and commercialize products resulting from the collaboration. 
  • Proteovant has the option to co-develop and co-commercialize the second of the two Blueprint Medicines-optioned programs in the U.S.
  • Proteovant will receive a $20 million upfront payment and be eligible for an additional $632 million in milestone payments plus tiered royalties from mid-to high-single digits on net sales on the first two programs targets.
  • Price Action: BPMC shares are down 0.16% at $62.08 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!